In multiple sclerosis (MS) treatment, do fewer circulating lymphocytes mean better results? A new real-world study says—surprisingly—not really.

For years, neurologists have speculated that treatment-induced lymphopenia—abnormally low levels of lymphocytes in the blood—might signal how well certain MS drugs are working. Fingolimod and dimethyl fumarate (DMF), two widely used oral disease-modifying therapies (DMTs), both commonly reduce lymphocyte counts. But does this immunosuppressive fingerprint actually correspond to disease control—or merely a side effect?

Researchers at the University of Genoa set out to clarify this question in a large real-life MS cohort, offering fresh insights that challenge assumptions about biomarkers, immune suppression, and drug efficacy.

Real-World Evidence: A Snapshot
In this retrospective observational study, the team followed 212 MS patients—137 on fingolimod and 75 on DMF—for at least 12 months. They tracked absolute lymphocyte counts (ALCs) at baseline, 6 months, and 12 months, alongside clinical outcomes such as relapses, MRI disease activity, disability progression (measured by the EDSS), and achievement of NEDA-3 (No Evidence of Disease Activity).

Importantly, they excluded anyone who had switched between fingolimod and DMF to avoid confounding factors.

Lymphocyte Drops? Yes. Treatment Response? Not So Much.
Fingolimod-treated patients, as expected, had a much steeper drop in lymphocyte counts than those on DMF. At 12 months, 75% of fingolimod patients showed grade II or III lymphopenia compared to just 15% of DMF patients.

Despite this dramatic immunological shift, no association was found between lymphocyte levels (absolute counts or percent decrease) and treatment outcomes. Whether patients achieved NEDA-3 or experienced relapses, their lymphocyte counts didn't seem to matter. This finding holds both for fingolimod and DMF, and challenges prior assumptions that a stronger lymphopenic response equates to better therapeutic control.

What About Infections?
A common concern with lymphopenia is infection risk. Surprisingly, even among those with moderate-to-severe lymphopenia, infection rates were not significantly higher. Among fingolimod users, 11.6% experienced infections; for DMF, it was 6.6%. These included minor viral infections such as herpes simplex and mild respiratory illnesses—no red flags suggesting that low lymphocytes alone predicted infectious complications.

Who’s at Risk for Lymphopenia?
While lymphocyte levels didn’t predict treatment response, some baseline characteristics did predict who would develop lymphopenia:

Lower baseline ALC and more prior therapies increased the odds in both drug groups.

Female sex and higher EDSS scores independently predicted lymphopenia in fingolimod users.

These insights might help clinicians anticipate which patients are more likely to require closer immune monitoring.

Mechanisms Beyond Lymphocytes?
Why doesn't lymphopenia predict outcomes? One reason may be that both fingolimod and DMF act through mechanisms beyond just reducing lymphocytes. Fingolimod affects CNS-resident immune cells and supports remyelination, while DMF is known to modulate oxidative stress, microglial activation, and brain iron metabolism. In other words, their therapeutic reach goes beyond what’s measurable in peripheral blood.

Clinical Implications: Don’t Overinterpret Lymphocyte Drops
This study provides a crucial takeaway for neurologists: a drop in lymphocyte count shouldn't be overinterpreted as a sign of treatment efficacy—or failure. Nor should it trigger automatic concern for infection unless severe or persistent.

What matters more may be personalized patient profiling—age, sex, disability level, and treatment history—to inform therapy planning and monitoring strategies.

Bottom Line
In the evolving landscape of MS care, this real-world study reminds us that not all biomarkers are as straightforward as they seem. Fingolimod and DMF may induce lymphopenia, but those changes alone do not reflect short-term efficacy or infection risk. It’s a nuanced insight that emphasizes the complexity of MS immunotherapy—and the need for comprehensive, individualized clinical judgment.

Disclaimer: This blog post is based on the information provided in the cited scientific article. It aims to provide an accessible summary of the research findings and should not be considered as definitive medical advice. For any health concerns, please consult with a qualified healthcare professional.

Reference:
Boffa, G., Bruschi, N., Cellerino, M., Lapucci, C., Novi, G., Sbragia, E., ... & Inglese, M. (2020). Fingolimod and dimethyl-fumarate-derived lymphopenia is not associated with short-term treatment response and risk of infections in a real-life MS population. CNS drugs, 34, 425-432.